LCA-0321

Asset

Selectively degrades disease-driving thyroid-stimulating hormone receptor autoantibodies through lysosomal targeting.

Stage
Phase 1
Modality
Not known
Target
Not known
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets